ROCKET PHARMACEUTICALS, INC. AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee SECOND SUPPLEMENTAL INDENTURE Dated as of February 20, 2020 to Indenture for Senior Debt Securities Dated as of August 5, 2016 6.25% Convertible Senior Notes due 2022Supplemental Indenture • February 20th, 2020 • Rocket Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
SECOND SUPPLEMENTAL INDENTURE dated as of February 20, 2020 (this “Supplemental Indenture”), between ROCKET PHARMACEUTICALS, INC. (f/k/a Inotek Pharmaceuticals Corporation), a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01), supplementing the Indenture for Senior Debt Securities dated as of August 5, 2016, between the Issuer and the Trustee (the “Base Indenture” and the Base Indenture, as amended and supplemented by this Supplemental Indenture, and as it may be further amended or supplemented from time to time with respect to the Notes, the “Indenture”).
AMENDMENT TO FIRST SUPPLEMENTAL INDENTURESupplemental Indenture • February 20th, 2020 • Rocket Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
AMENDMENT TO FIRST SUPPLEMENTAL INDENTURE, dated as of February 18, 2020 (this “Amendment”), between Rocket Pharmaceuticals, Inc. (f/k/a Inotek Pharmaceuticals Corporation), a Delaware corporation (the “Company”), and Wilmington Trust, National Association, a national banking association organized and existing under the laws of the United States of America, as trustee (the “Trustee”).
